cellgevity glutathione Max International Cellgevity, Advanced UK max the glutathione company Max

The most common clinical trial dose is 24 IU administered intranasally

Additional etiologies that may mimic Reyes syndrome include viral infections, neuromuscular diseases, adverse drug reactions, and exposure to toxic chemicals and plants that cause hepatocellular damage and encephalopathy

Starting treatment within 48 hours of symptom onset maximizes effectiveness while potentially increasing side effect intensity during the first 2-3 days of the 5-day course

Commercial Development: In August 2025, Jocasta Neuroscience raised $35 million in Series A funding to advance JN-0413, a proprietary -klotho formulation, through Phase 1 trials with IND submission planned for Q4 2026